Preclinical Efficacy of Novel Dual PI3K/mTOR Inhibitor CMG002 As Potential Anti-Hepatocellular Carcinoma Agent

被引：0
|
作者：
Kim, Mi Na [1 ]
Lee, Seung Min [2 ]
Hwang, Seong-Gyu [3 ]
机构：
[1] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Pochon, South Korea
[2] CHA Univ, CHA Bundang Med Ctr, Inst Clin Res, Pochon, South Korea
[3] Cha Bundang Med Ctr, Seongnam, South Korea
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2233
引用
收藏
页码：1266A / 1266A
页数：1
相关论文
共 50 条
  • [21] Apitolisib. Dual PI3K/mTOR inhibitor, Oncolytic
    de Lartigue, Jane
    DRUGS OF THE FUTURE, 2013, 38 (10) : 671 - 678
  • [22] Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines
    Masuda, Mitsuhiro
    Shimomura, Manami
    Kobayashi, Ken
    Kojima, Shuji
    Nakatsura, Tetsuya
    ONCOLOGY REPORTS, 2011, 26 (05) : 1273 - 1279
  • [23] Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
    Zhou, Qian
    Lui, Vivian W. Y.
    Yeo, Winnie
    FUTURE ONCOLOGY, 2011, 7 (10) : 1149 - 1167
  • [24] Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
    Sun, Eun Jin
    Wankell, Miriam
    Palamuthusingam, Pranavan
    McFarlane, Craig
    Hebbard, Lionel
    BIOMEDICINES, 2021, 9 (11)
  • [25] GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy
    Gu, Juan
    Yang, Lianjuan
    Gaughan, Dennis C.
    He, Ling
    Shen, Weina
    Mavis, Cory
    Hernandez-Ilizaliturri, Francisco J.
    BLOOD, 2018, 132
  • [26] Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models
    Melchior, Maxine A.
    Guo, Xuemei
    Donoho, Gregory P.
    Iversen, Philip W.
    Doman, Thompson N.
    Brahmachary, Manisha
    Gong, Xueqian
    Hall, Gerald E.
    Manro, Jason R.
    Yao, Yung-mae M.
    Buchanan, Sean
    Smeal, Tod
    Kalos, Michael D.
    Novosiadly, Ruslan D.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [27] Discovery and research of a novel dual PI3K/mTOR inhibitor, DS-7423
    Shiose, Yoshinobu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 48P - 48P
  • [28] A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
    Sun, Xin
    Yang, Yang
    Xia, Lulu
    Wang, Shiyu
    Fu, Yuxing
    Zhu, Yuxuan
    Xu, Shan
    Zhu, Wufu
    Zhu, Wufu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [29] DHW-208, A Novel Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Has Anti-Hepatocellular Carcinoma Activity Through Promoting Apoptosis and Inhibiting Angiogenesis
    Wang, Shu
    Wu, Yuting
    Liu, Mingyue
    Zhao, Qingchun
    Jian, Lingyan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
    Smith, Aleisha M.
    Xiong, Jessie
    Hunter, Lucas
    Jordan, Jamie
    Clark, Kelly
    Darr, David B.
    Norman, Sharpless
    Perou, Charles M.
    Kim, William Y.
    CANCER RESEARCH, 2015, 75
12345